Eden Research Plc · LSE:EDEN
Eden Research — Investor Presentation (2015)
21 slides from Eden Research's investor presentation, 2015
Slide 1: Biological Products Micro-Encapsulation Company Presentation
BIOLOGICAL PRODUCTS M I C R O - E N C A P S U L AT I O N COMPANY PRESENTATION www.edenresearch.com Eden Research plc
Slide 2: Who are we?
Who are we? Eden Research (“Eden”) is an AIM listed, UK company with a patented platform technology which is used to create natural products using terpenes We are a low overhead business that generates royalty revenue through the exploitation of our intellectual property We partner with businesses t
Slide 3: What do we do?
What do we do? Eden owns a unique platform technology (GO-E™) which is used to create highly effective, natural products as well as acting as an add-on technology to existing synthetic products to provide significant improvements GO-E is a natural micro-encapsulation system which enables slow releas
Slide 4: What are the benefits of the GO-E technology?
What are the benefits of the GO-E technology? Terpene based products Terpenes have well documented biocidal activity, but, can be difficult to use commercially due to their inherent volatility The GO-E system allows these volatile active substances to be delivered to their target in a controlled man
Slide 5: What are the benefits of the GO-E technology?
What are the benefits of the GO-E technology? Value add technology (“Co-encapsulation”) The GO-E system is able to: provide slow release delivery, increasing residual effect tackle resistance build-up experienced by old molecules provide further IP protection Example of potential: Until recently, on
Slide 6: How does GO-E work? (Tech 1)
How does GO-E work? (Tech 1) Carrier Encapsulated Particles Terpene Terpene payload released on contact with water As particle dries, pores close and trap Terpene Payload remaining terpenes Stabilised aqueous emulsion Cycle repeated until all payload is released Encapsulation enables use of terpenes
Slide 7: How does GO-E work? (Tech 2)
How does GO-E work? (Tech 2) “Technology Two” has been licensed from the University of Massachusetts Medical School on an exclusive basis for the areas of agrochemicals, health and beauty and animal health “Technology Two” provides greater control and increased delay over the release of active subst
Slide 8: What is Eden's business model?
What is Eden’s business model? Eden’s business model generally works on the basis of 1% of the relevant market for individual products in upfront and milestone payments, followed by annual royalties of, typically, up to 10% on net sales Low cost base – R & D outsourced to Contracted Research Organis
Slide 9: What is Eden's first agrochemical product, 3AEY?
What is Eden’s first agrochemical product, 3AEY? 3AEY is a combination of three terpenes which is Performance of 3AEY in regulatory trials is an effective botryticide and which was developed equivalent to commercial standards and often by Eden better when disease pressure is high Global markets wort
Slide 10: What are the agrochemical opportunities?
What are the agrochemical opportunities? NEMATODES • The second product developed by Eden uses a different combination of two of the terpenes being registered in the EU for 3AEY • The nematodes market is significant (c.$1bn worldwide) and suffering from existing traditional chemical products being b
Slide 11: What are the current developments in agrochemicals?
What are the current developments in agrochemicals? EU approval for the three actives received in May 2013 First EU approval for 3AEY received in May 2015 Approvals of 3AEY in other southern EU zone Member States expected in Q3, 2015 in addition to Kenya Active substance dossiers completed for a num
Slide 12: What are the animal health opportunities?
What are the animal health opportunities? BAYER ANIMAL HEALTH • Exclusive licence agreement signed with Bayer Animal Health (“Bayer”) for North America • Flea, tick and shampoo products have been developed by Bayer over the past three years • Significant marketing campaign and products launch expect
Slide 13: What other opportunities are there?
What other opportunities are there? BIOCIDES • Licence agreement signed with TerpeneTech Limited for global rights to biocidal products (such as ants, cockroaches, mosquitoes) using Eden’s technologies • Licence fees totalling €0.1m, plus royalties on net sales of product of between 5 – 10% HEAD-LIC
Slide 14: Eden Research plc
Eden Research plc Keble House, Church End, South Leigh, Witney, OXON, OX29 6UR Tel: +44 (0) 1993 862761 Fax: +44 (0) 1993 776480 Email: info@edenresearch.com
Slide 15: Directors and Advisors
Directors and Advisors Tom Lupton - Non-Executive Chairman Sean Smith – Chief Executive Officer Alex Abrey - Chief Financial Officer Robin Cridland – Non-Executive Director Dr Gary Ostroff - Chairman of Scientific Advisory Board 14
Slide 16: Executive Directors
Executive Directors Sean Smith – Chief Executive Officer Sean has a bachelors degree in microbiology and over 25 years of experience in the speciality chemicals and industrial biotechnology industries. He has held senior commercial leadership roles ranging from sales and marketing to business manage
Slide 17: Non-Executive Directors
Non-Executive Directors Tom Lupton – Non-Executive Chairman Tom studied Agriculture and Forest Sciences at Oxford University, and spent 23 years working with the Commonwealth Development Corporation developing and managing large agribusiness companies in Southern Africa, culminating in being Managin
Slide 18: Non-Executive Directors
Non-Executive Directors Robin Cridland – Non-Executive Director Rob currently serves as Chief Financial Officer and Company Secretary of Revolymer plc. He joined Revolymer in September 2008 from Renovo Group plc where he spent seven years as Executive Director of Finance and Business Development. He
Slide 19: Advisors
Advisors Gary Ostroff PhD – Chairman of Scientific Advisory Board Gary is a microbiologist with over 20 years of research and development (R&D) experience in the biopharmaceutical, functional food and dietary supplement industries. He has served as Vice President of R&D for several US companies, inc
Slide 20: Patent portfolio
Patent portfolio Eden’s patent families comprise: Patent 1 – Master Encapsulation “Terpene – Containing Compositions and Methods of Making and Using Them” This is the Company’s encapsulation platform technology and relates to terpene components encapsulated within hollow glucan particles (e.g. yeast
Slide 21: Disclaimer
Disclaimer This presentation has been prepared by, and is the sole responsibility of, Eden Research Plc (the ‘‘Company’’) and its directors. The information contained herein is as of the date hereof and subject to change, completion or amendment without notice. There may have been changes in matters